Toll Free: 1-888-928-9744

CTI BioPharma Corp. - Product Pipeline Review - 2015

Published: Jul, 2015 | Pages: 56 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

CTI BioPharma Corp. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'CTI BioPharma Corp. - Product Pipeline Review - 2015', provides an overview of the CTI BioPharma Corp.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CTI BioPharma Corp.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of CTI BioPharma Corp. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of CTI BioPharma Corp.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the CTI BioPharma Corp.'s pipeline products

Reasons to buy

- Evaluate CTI BioPharma Corp.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of CTI BioPharma Corp. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the CTI BioPharma Corp.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of CTI BioPharma Corp. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of CTI BioPharma Corp.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of CTI BioPharma Corp. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 CTI BioPharma Corp. Snapshot 5 CTI BioPharma Corp. Overview 5 Key Information 5 Key Facts 5 CTI BioPharma Corp. - Research and Development Overview 6 Key Therapeutic Areas 6 CTI BioPharma Corp. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 CTI BioPharma Corp. - Pipeline Products Glance 11 CTI BioPharma Corp. - Late Stage Pipeline Products 11 Filing rejected/Withdrawn Products/Combination Treatment Modalities 11 Phase III Products/Combination Treatment Modalities 12 CTI BioPharma Corp. - Clinical Stage Pipeline Products 13 Phase II Products/Combination Treatment Modalities 13 Phase I Products/Combination Treatment Modalities 14 CTI BioPharma Corp. - Drug Profiles 15 paclitaxel poliglumex 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 pixantrone dimaleate 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 pacritinib 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 lisofylline 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 tosedostat 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 CTI BioPharma Corp. - Pipeline Analysis 30 CTI BioPharma Corp. - Pipeline Products by Target 30 CTI BioPharma Corp. - Pipeline Products by Route of Administration 31 CTI BioPharma Corp. - Pipeline Products by Molecule Type 32 CTI BioPharma Corp. - Pipeline Products by Mechanism of Action 33 CTI BioPharma Corp. - Recent Pipeline Updates 34 CTI BioPharma Corp. - Dormant Projects 48 CTI BioPharma Corp. - Discontinued Pipeline Products 49 Discontinued Pipeline Product Profiles 49 CT-2584 49 nortopixantrone 49 topixantrone 49 CTI BioPharma Corp. - Company Statement 50 CTI BioPharma Corp. - Locations And Subsidiaries 54 Head Office 54 Other Locations & Subsidiaries 54 Appendix 55 Methodology 55 Coverage 55 Secondary Research 55 Primary Research 55 Expert Panel Validation 55 Contact Us 55 Disclaimer 56
List of Tables
CTI BioPharma Corp., Key Information 5 CTI BioPharma Corp., Key Facts 5 CTI BioPharma Corp. - Pipeline by Indication, 2015 7 CTI BioPharma Corp. - Pipeline by Stage of Development, 2015 9 CTI BioPharma Corp. - Monotherapy Products in Pipeline, 2015 10 CTI BioPharma Corp. - Filing rejected/Withdrawn, 2015 11 CTI BioPharma Corp. - Phase III, 2015 12 CTI BioPharma Corp. - Phase II, 2015 13 CTI BioPharma Corp. - Phase I, 2015 14 CTI BioPharma Corp. - Pipeline by Target, 2015 30 CTI BioPharma Corp. - Pipeline by Route of Administration, 2015 31 CTI BioPharma Corp. - Pipeline by Molecule Type, 2015 32 CTI BioPharma Corp. - Pipeline Products by Mechanism of Action, 2015 33 CTI BioPharma Corp. - Recent Pipeline Updates, 2015 34 CTI BioPharma Corp. - Dormant Developmental Projects,2015 48 CTI BioPharma Corp. - Discontinued Pipeline Products, 2015 49 CTI BioPharma Corp., Subsidiaries 54



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify